Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DJ6AW5
|
|||
| Drug Name |
CT-041
|
|||
| Drug Type |
CAR-T cell therapy
|
|||
| Indication | Gastric cancer [ICD-11: 2B72] | Phase 1/2 | [1] | |
| Company |
CARsgen Houston, TX
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Claudin-18 (CLDN18) | Target Info | . | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Tight junction | ||||
| Leukocyte transendothelial migration | ||||
| Hepatitis C | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Reactome | Tight junction interactions | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04404595) Open-label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects With Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of CARSGEN | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.